PURPOSE: To analyze the patterns of failure and the toxicity profile of intraoperative electron beam radiotherapy (IOERT) after resection of soft tissue sarcomas of the extremities (STS). PATIENTS AND METHODS: Forty-five patients with extremity STS were treated with IOERT and moderate-dose postoperative radiotherapy (45-50 Gy). Twenty-six patients were treated for primary disease (PD) and 19 patients for an isolated recurrence (ILR). Tumor size was >5 cm (maximum diameter) in 36 patients (80%), and high-grade histology in PD patients was present in 14 patients (54%). In nine patients, IOERT was used alone, due to previous irradiation or patient refusal. Chemotherapy (neoadjuvant and/or adjuvant) was mainly given to high-grade tumors. RESULTS: Nine patients relapsed in the extremity (20%), and 12 patients in distant sites (28%). Actuarial local control at 5 years was 88% for patients with negative/close margins and 57% for patients presenting positive margins (P=0.04). Five patients (11%) developed neuropathy associated with the treatment. Extremity preservation was achieved in 40 patients (88%). With a median follow-up of 93 months (range: 27-143 months) for the patients at risk, 25 patients remain alive (a 7-year actuarial survival rate of 75% for PD and 47% for ILR; P=0.01). CONCLUSIONS: IOERT combined with moderate doses of external beam irradiation yields high local control and extremity preservation rates in resected extremity STS. Peripheral nerves in the IOERT field are dose-limiting structures requiring a dose compromise in the IOERT component to avoid severe neurological damage.
PURPOSE: To analyze the patterns of failure and the toxicity profile of intraoperative electron beam radiotherapy (IOERT) after resection of soft tissue sarcomas of the extremities (STS). PATIENTS AND METHODS: Forty-five patients with extremity STS were treated with IOERT and moderate-dose postoperative radiotherapy (45-50 Gy). Twenty-six patients were treated for primary disease (PD) and 19 patients for an isolated recurrence (ILR). Tumor size was >5 cm (maximum diameter) in 36 patients (80%), and high-grade histology in PDpatients was present in 14 patients (54%). In nine patients, IOERT was used alone, due to previous irradiation or patient refusal. Chemotherapy (neoadjuvant and/or adjuvant) was mainly given to high-grade tumors. RESULTS: Nine patients relapsed in the extremity (20%), and 12 patients in distant sites (28%). Actuarial local control at 5 years was 88% for patients with negative/close margins and 57% for patients presenting positive margins (P=0.04). Five patients (11%) developed neuropathy associated with the treatment. Extremity preservation was achieved in 40 patients (88%). With a median follow-up of 93 months (range: 27-143 months) for the patients at risk, 25 patients remain alive (a 7-year actuarial survival rate of 75% for PD and 47% for ILR; P=0.01). CONCLUSIONS: IOERT combined with moderate doses of external beam irradiation yields high local control and extremity preservation rates in resected extremity STS. Peripheral nerves in the IOERT field are dose-limiting structures requiring a dose compromise in the IOERT component to avoid severe neurological damage.
Authors: Esther Carbó-Laso; Pablo Sanz-Ruiz; José Antonio Calvo-Haro; Miguel Cuervo-Dehesa; Rubén Pérez-Mañanes; Lydia Mediavilla-Santos; Coral Sánchez-Pérez; Ana Álvarez-González; Javier Vaquero-Martín Journal: Int J Clin Oncol Date: 2017-07-17 Impact factor: 3.402
Authors: Adam Schwartz; Alanna Rebecca; Anthony Smith; William Casey; Jonathan Ashman; Leonard Gunderson; Kelly Curtis; Yu-Hui H Chang; Christopher Beauchamp Journal: Clin Orthop Relat Res Date: 2013-06-28 Impact factor: 4.176
Authors: M Krengli; F A Calvo; F Sedlmayer; C V Sole; G Fastner; M Alessandro; S Maluta; R Corvò; E Sperk; M Litoborski; C Pisani; C Fillini; F Fusconi; M F Osti; L Tomio; H Marsiglia; A Ciabattoni; W Polkowski; A Di Grazia; A Gava; A Kuten; C Iotti; C Gonzalez; M Sallabanda; J-B Dubois; G Catalano; V Valentini Journal: Strahlenther Onkol Date: 2013-07-12 Impact factor: 3.621
Authors: R Correa; J Gómez-Millán; M Lobato; A Fernández; R Ordoñez; C Castro; Y Lupiañez; J A Medina Journal: Clin Transl Oncol Date: 2018-02-23 Impact factor: 3.405
Authors: Felipe A Calvo; Claudio V Sole; Alfredo Polo; Mauricio Cambeiro; Angel Montero; Ana Alvarez; Miguel Cuervo; Mikel San Julian; Rafael Martinez-Monge Journal: Strahlenther Onkol Date: 2014-04-09 Impact factor: 3.621
Authors: Quy N H Tran; Anne C Kim; Alexander R Gottschalk; William M Wara; Theodore L Phillips; Richard J O'donnell; Vivian Weinberg; Daphne A Haas-Kogan Journal: Sarcoma Date: 2006